C. Difficile Treatment: Fidaxomicin
A discussion on fidaxomicin as treatment for C. difficile infections and clinician feedback on current challenges that impact its use in clinical practice.
Video Player is loading.
Recent Videos
Education and Advocacy in DC: The PLF C Diff Summit and Lobby Day
Vaxart's Oral Norovirus Vaccine: Key Study Findings and Future Plans
Advances in Mini Gut Organoid Models Reveal Key Insights into Norovirus Replication
Targeting C difficile with Oxygen-Based Therapy
Targeting the C Diff Pathogen and Its Immune-Suppressing Toxins
mRNA Vaccine Shows Potential for C difficile Infections
Two Years After its FDA Approval, Rebyota Continues to Show Efficacy and Safety
Due to FDA Policy Change, Fecal Microbiota Transplants Are in a Tenuous Position
Targeted Prophylaxis Reduces Hospital-Onset C difficile Infections in High-Risk Patients
Tips for Talking with Patients about Fecal Microbiota Transplant for Recurrent C. difficile Infections
Related Content
